H. Morio

发表

AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts

J. Hirose, M. Inami, Koji Nakamura, 2017, European journal of pharmacology.

Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low‐dose tacrolimus, for renal allograft rejection in non‐human primates

S. Tsujimoto, J. Hirose, M. Inami, 2018, International immunopharmacology.

In vivo pharmacologic profile of YM158, a new dual antagonist for leukotriene D4 and thromboxane A2 receptors.

T. Yamada, K. Honda, K. Miyata, 2000, Japanese journal of pharmacology.

Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyper-responsiveness in guinea pigs.

T. Yamada, K. Honda, K. Miyata, 2000, Japanese journal of pharmacology.

YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models.

K. Honda, T. Morokata, H. Morio, 2007, European journal of pharmacology.

Effect of combined leukotriene D(4) and thromboxane A(2) receptor antagonist on mediator-controlled resistance in guinea pigs.

T. Yamada, H. Morio, K. Ohga, 2000, European journal of pharmacology.

A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects

H. Fushiki, M. Kamohara, H. Morio, 2022, mAbs.

Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors.

Ayako Moritomo, Takayuki Inoue, M. Inami, 2017, Bioorganic & medicinal chemistry.

THU0101 ASP015K: A Novel Jak Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats

N. Seki, M. Inami, M. Ito, 2013 .